Search
Ethosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: PETIMID 250 MG KAPSUL, 50 ADET, Ethosuximid neuraxpharm 50 mg/ml Lösung zum EinnehmenDoravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigational[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: PİFELTRO 100 MG FİLM KAPLI TABLET, 30 ADETTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalThe FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: KADCYLA 100 MG IV INFUZYONLUK COZELTI KONSANTRESI ICIN TOZ, Kadcyla 100 mg powder for concentrate for solution for infusionLeflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 4-ISOXAZOLECARBOXAMIDE, 5-METHYL-N-(4-(TRIFLUOROMETHYL)PHENYL)-, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamideNabumetone
go.drugbank.com/drugs/DB00461ApprovedNabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID). … [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action.
Mixtures: NuDroxiPAK N-500Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSalmeterol
go.drugbank.com/drugs/DB00938ApprovedInvestigational[A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542] … [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol].
Mixtures: SERETIDE 50/100 ACCUHALER 50 mcg/100 mcg, ACTIONFLU® 100/50 MCGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAzelastine
go.drugbank.com/drugs/DB00972ApprovedInvestigationalAzelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic … [L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.
Mixtures: DYMİSTA 137 MCG + 50 MCG BURUN SPREYİ, SÜSPANSİYON, 23 G, DYMİSTA 137 MCG + 50 MCG BURUN SPREYİ, SÜSPANSİYON, 6,4 GCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesAmorolfine
go.drugbank.com/drugs/DB09056ApprovedWithdrawnAmorolfine is marketed as Curanail, Loceryl, Locetar, and Odenil. … Amorolfine 5% nail lacquer in once or twice weekly applications is 60-71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment (after six months of treatment
Products: Amorocutan 50 mg/ml wirkstoffhaltiger Nagellack, Exorolfin 50 mg/ml - wirkstoffhaltiger NagellackDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalThis is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesProducts: FAMPYRA 10 MG UZATILMIŞ SALIMLI TABLET,56 TABLET, HALFPRİN 10 MG UZATILMIŞ SALIMLI TABLET, 56 ADETBevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A193272,A193275,L12648] Avastin was subsequently approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. … [A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target.
Products: ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/4 ML, ZİRABEV 100 MG/4 ML İNFÜZYONLUK ÇÖZELTİ, 1 ADET